Analysts start coverage on Medline with bullish ratings
12/01/2026 09:49
** At least six brokerages start coverage on medical supplies maker and distributor Medline MDLN.O with bullish ratings as industry-mandated quiet period ends ** Medline made its public-market debut in December, valuing co at $46 billion in the largest U.S. IPO since Rivian's RIVN.O 2021 listing ** JPM says MDLN’s recent market share gains are likely to endure, with co well-placed to keep winning business by offering cost savings alongside strong service ** Jefferies says co is expected to grow at high single‑digit pace or better, with growth split evenly between existing customers and new client wins ** Trading price of $40.52 as of Friday's close is higher than IPO price of $29 ** Ratings and PTs on the stock:
| Brokerage | Rating | PT |
| J.P. Morgan | Overweight | $50 |
| Leerink Partners | Outperform | $48 |
| Baird | Outperform | $48 |
| RBC | Outperform | $47 |
| Piper Sandler | Overweight | $50 |
| Jefferies | Buy | $50 |
Recent news on Medline
See all newsU.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Medline Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Medline Reports Second Quarter And First Six Months 2026 Results
Medline Q2 profit sinks on Tracy fire-related charges